Venus Medtech (Hangzhou) Inc. ("Venus Medtech"), is the leader in transcatheter structural heart valvular therapies in China. The company is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. Venus Medtech is founded in 2009...
By order of the Board Venus Medtech (Hangzhou) Inc. Min Frank Zeng Chairman June 21, 2023 –1– Notes: 1. The register of members of H Shares of the Company will be closed from Friday, July 7, 2023 to Wednesday, July 12, 2023 (both days inclusive). Holders of H Shares and ...
Venus Medtech HangZhou Inc (Venus MedTech) is a medical device company that develops and commercializes transcatheter heart valve products for structural heart diseases. The company's product portfolio includes venusA- valve, venusP- valve, V8/TAV8, and TriGUARD3 CEP device. Its products find ap...
Venus Medtech (Hangzhou) Inc. (02500.HK) is committed to structural heart innovation. We are developing and commercializing comprehensive solutions for structural heart disease. Our robust pipeline, encompassing all four heart valves from TAVR, TPVR, TMVR, and TTVR t...
美通社企業新聞室爲您提供杭州启明医疗器械股份有限公司 VENUS MEDTECH (HANGZHOU) INC.的相關企業新聞稿資訊,查看杭州启明医疗器械股份有限公司 VENUS MEDTECH (HANGZHOU) INC.新聞資訊,請登錄杭州启明医疗器械股份有限公司 VENUS MEDTECH (HANGZHOU) INC.企業新聞頻道。
Venus Medtech下一财年的预估营收一致预期标准差是zero。. 查看Venus Medtech (Hangzhou) Inc.的营收一致预期标准差趋势、图表等
Venus Medtech (Hangzhou) Inc.的公允价值下行边际 (InvestingPro)排名为第-名,处于板块内-的水平。下表提供了更多数据的摘要: 板块医疗保健的公允价值下行边际 (InvestingPro) 经济风险区类别 发展中 全部成分股 1,179 包括的成分股 1,131 分钟 -65.1% 最大值 42.4% 中位数 -2.4% 平均值 -4.4% 标准差 23...
11 月 10 日,香港交易所披露了杭州启明医疗器械股份有限公司Venus Medtech (Hangzhou) Inc.(以下简称“启明医疗”)通过聆讯后的招股书。启明医疗此前于 8 月 5 日在港交所递表。 启明医疗,成立于2009年,是中国领先的经导管心脏瓣膜医疗器械企业,拥有涵盖全部四个心脏瓣膜的产品管线。其自主研发的产品VenusA-Val...
HANGZHOU, China,April 28, 2017/PRNewswire/ -- Venus Medtech (Hangzhou) Inc., announced onApril 25ththat its transcatheter aortic valve system - Venus A-valve - has been approved by China Food and Drug Administration ("CFDA") (registration no.: 20173460680) for sale inChina. This marks the...
杭州启明医疗器械股份有限公司(VenusMedtech(Hangzhou) Inc., 2500.HK, 简称∶启明医疗)在香港首次公开募股(IPO)的所得款项净额约为24.1亿港元(约合3.078亿美元)。该公司是近来寻求在香港股市上市的一系列医疗公司之一。 ?明医疗周一在提交给香港交易所的一份文件中说,该公司以每股33.00港元的价格发售了7,854万股...